阿奇霉素序贯疗法治疗小儿支原体肺炎的临床效果及安全性研究

Clinical efficacy and safety study of azithromycin sequential therapy on Mycoplasma pneumonia in children

目的：研究分析阿奇霉素序贯疗法治疗小儿支原体肺炎的临床效果及其安全性。方法选取2011年11月~2013年11月在本院接受治疗的120例小儿支原体肺炎患儿，随机分为观察组和对照组，每组60例。观察组患儿采用阿奇霉素序贯疗法治疗，对照组单纯采用红霉素治疗，比较两组患儿的治疗效果、症状消失时间及不良反应情况。结果观察组总有效率为96.7%，显著高于对照组的78.3%，差异有统计学意义（P＜0.05）；观察组退热、咳嗽及肺部湿啰音消失时间均短于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为3.33%，低于对照组的15.00%，差异有统计学意义（P＜0.05）。结论阿奇霉素序贯疗法治疗小儿支原体肺炎临床效果显著，不良反应少，值得临床推广应用。

Objective To explore and analyse the clinical efficacy and safety of azithromycin sequential therapy in the treatment of Mycoplasma pneumonia in children. Methods 120 cases of children patients with Mycoplasma pneumonia who were treated in our hospital from November 2011 to November 2013 were selected and randomly divided into ob-servation group and control group,with 60 patients in each group.Patients in the observation group were received azithromycin sequential therapy,while the control group were received erythromycin only.Curative effect,symptom disap-pearing time and adverse events were compared between the two groups. Results Total effective rate in the observation group was 96.7%,significantly higher than 78.3% in the control group,the difference was significant （P〈0.05）;disappear-ing time of fever,cough and pulmonary moist rales was shorter than that in the control group respectively,the difference was significant （P〈0.05）;the incidence of adverse events in the observation group was 3.33%,lower than 15.00% in the control group,the difference was significant （P〈0.05）. Conclusion Azithromycin sequential therapy for children patients with Mycoplasma pneumonia has a significant clinical effect and rare adverse events,which is worthy of clinical promo-tion and application.